International Stem Cell CORP
International Stem Cell Corp. is a clinical-stage biotechnology company that develops human parthenogenetic stem cell-based therapies and also operates two commercial businesses: Lifeline Cell Technology for human cell research products and Lifeline Skin Care for cosmetic products. The company combines early-stage regenerative medicine development with revenue-generating biomedical and consumer product lines.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueHuman primary cells, media, and related research tools sold through LCT.
Lifeline Skin Care branded cosmetic products sold online and through ecommerce partners.
Preclinical and clinical-stage stem cell programs targeting neurological diseases.
UniStemCell™ hpSC lines and related proprietary cell differentiation know-how.
Customers
The company sells to biomedical researchers, laboratories, and commercial partners that need human cell culture products for research and assay development. Its cosmetic products are sold directly to consumers through a branded website, Amazon, and ecommerce partners, while research products are distributed through internal sales, OEM partners, and brand distributors in Europe and Asia. The therapeutic programs do not yet generate revenue and are aimed at future clinical and partnering opportunities.
Buy primary human cells and media for cell culture, assay development, and translational research.
Buy branded cosmetic products directly online for personal care use.
Purchase or distribute LCT products to extend market reach in Europe and Asia.
Potential partners for licensing, clinical development, manufacturing, and commercialization of hpSC programs.
Strategy
Management is focused on funding and advancing stem cell therapeutic programs while using the commercial businesses to support operations. The near-term strategy emphasizes partnerships, regulatory progress, and capital raising, because the principal therapeutic operations currently generate no revenue. At the same time, the company is trying to improve product mix, manufacturing efficiency, and ecommerce/distributor execution in the biomedical and skincare businesses.
Clinical programs are the long-term value driver but require substantial time and capital.
The company states it needs additional capital to sustain operations and advance development.
Biomedical and skincare sales help offset R&D burn and support liquidity.
Better production efficiency can raise gross profit in the existing commercial businesses.
Geography
2025The company is headquartered in the United States and sells its cosmetic products domestically through its own website, Amazon, and ecommerce partners. Its biomedical research products are marketed through internal sales, OEM partners, and distributors in Europe and Asia, making international channel access important even though the therapeutic pipeline remains U.S.-based and pre-revenue. Geography matters because the commercial businesses depend on online and distributor reach, while the development business is exposed to U.S. regulatory and funding conditions.
Share of the revenue the company reports by geography.
Risks
The company faces substantial financing risk because its therapeutic programs are pre-revenue and management says existing cash is insufficient without additional funding. Commercial execution risk is also meaningful, since revenue depends on ecommerce demand, distributor performance, and maintaining product quality in regulated cell-culture and cosmetic categories. Broader biotech risks include clinical failure, regulatory delays, patent costs, and the possibility that partnerships require giving up economics or control.
Management says it needs significant additional capital to sustain operations and fund R&D.
Exposure: Corporate operations and clinical development
Cell-based therapies and cosmetics require ongoing regulatory oversight and quality control.
Exposure: FDA/GMP compliance and cosmetic product regulation
hpSC therapeutic candidates are early-stage and may not prove safe or effective.
Commercial products rely on a limited set of ecommerce, OEM, and distributor channels.
Exposure: LCT and LSC sales channels
Protecting stem cell technologies requires ongoing filing, prosecution, and defense costs.
Exposure: Proprietary cell lines and differentiation methods
Accounting
Judgemental itemsBiomedical sales and skincare sales have different margin profiles, so mix changes affect reported profitability.
Impact: Quarterly gross margin volatility
Development costs are expensed as incurred, making results sensitive to project timing and staffing.
Impact: Reported operating loss and comparability
Rent and facility costs are a meaningful part of overhead and can shift with occupancy and usage.
Impact: Operating expense trend
Interest expense on the note payable affects other expense and reflects financing dependence.
Impact: Net loss and liquidity
Management's ability to raise capital is a key estimate affecting financial statement interpretation.
Impact: Disclosure risk and valuation context
Similar listed companies
Publicly listed companies with a comparable business focus.
Stemtech Corp
STEK · Wholesale-Drugs, Proprietaries & Druggists' Sundries
Stemtech Corp develops and markets stem cell nutrition and personal care products, including dietary supplements, toothpaste, and skin-care items sold under proprietary brands.
BriaCell Therapeutics Corp.
BCTXZ · Pharmaceutical Preparations
Century Therapeutics, Inc.
IPSC · Biological Products, (No Diagnostic Substances)
Creative Medical Technology Holdings, Inc
CELZ · Biological Products, (No Diagnostic Substances)
Immatics N.V.
IMTX · Biological Products, (No Diagnostic Substances)
Celularity Inc
CELU · Pharmaceutical Preparations
Last updated: 24/09/2026